Hereditary hemorrhagic telangiectasia (HHT) is characterized by
telangiectasia and larger
arteriovenous malformations (AVM) in different organs. Mucocutaneous
telangiectasia can bleed and cause stigmatization, but the best treatment approach has not been defined yet. The aim of the study was to evaluate the efficacy and safety of dual
pulsed dye laser and
neodymium:
yttrium-aluminum-garnet (PDL-
Nd:YAG) laser treatment for mucocutaneous
telangiectasia in HHT patients. It is a retrospective case series, where clinical files of all HHT patients treated with PDL-
Nd:YAG laser at our Department between December 2010 and July 2019 were reviewed. Demographic, clinical, and treatment characteristics were recorded. The severity and degree of improvement were evaluated by three blinded examiners scoring pretreatment and posttreatment pictures on a 5-point scale. Patient satisfaction and procedure
pain were assessed using an ordinal scale (0-10). Forty-three treatment areas from 26 patients were analyzed. Lesions were predominantly located on the lower lip and cheeks. The median number of
laser sessions per patient was 3 (interquartile range [IQR] 2-4). The median global severity score at baseline was 2 and became 0 at endpoint (p < 0.0001), with a median improvement rate of 4 (IQR 3-4). All patients reported a high degree of satisfaction (median 9) and tolerable
pain (median 5). In conclusion, dual PDL-
Nd: YAG laser is a convenient, safe, and effective treatment option for mucocutaneous
telangiectasia in HHT patients.